Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma

Overview

The purpose of the study is to determine the safety and efficacy of intracranially implanted Carmustine in the treatment of patients with primary malignant glioma.

Full Title of Study: “Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2014

Detailed Description

Malignant gliomas recur mostly 2 cm within originated area. Local therapies therefore become particular important. Gliadel wafer developed in the States and marketed in the developed countries is an example of such treatments. The product in this study, Carmustine Sustained Release Implant (CASANT), is similar to that of Gliadel wafer as for the API(Active Pharmaceutical Ingredient), but different as for drug delivering system. As required, the preliminary clinical studies were conducted in China. Based on the results of phase I/II , 8-10 wafers containing given dose of BCNU will be administered intracranially in this phase III to the tumor resected cavity to investigate the safety and efficacy in the treatment of primary malignant glioma in 236 patients.

Interventions

  • Drug: Carmustine
    • As Experimental group, subjects will accept specified wafers of carmustine in the cavity while gliomas maximally be resected.
  • Procedure: tumor resection surgery
    • For this group, subjects will accept routine tumor resection surgery and place no implant wafers.

Arms, Groups and Cohorts

  • Experimental: Carmustine Sustained Release Implant
    • For subjects in this group, they will accept intracranially implanted carmustine intraoperatively.
  • Sham Comparator: Tumor Resection Surgery
    • For subjects in this control group, they accept no implants while gliomas maximally be resected.

Clinical Trial Outcome Measures

Primary Measures

  • Overall Survival
    • Time Frame: 15 months

Secondary Measures

  • Progress Free Survival
    • Time Frame: 15 months
  • Overall Survival Rate at 12 months
    • Time Frame: 15 months
  • Karnofsky Performance Status(KPS)
    • Time Frame: 15 months
  • Quality of Life(QOL)
    • Time Frame: 15 months
  • Safety of intracranially implanted carmustine after maximal tumor resection
    • Time Frame: 15 months
    • Occurrence rate of adverse event and serious adverse event revealed by laboratory test outcomes including blood routine and chemistry as well as physical examination, vital signs including blood pressure, temperature, respiratory rate , heart rate.

Participating in This Clinical Trial

Inclusion Criteria

  • Confirmation of high grade glioma(WHO III or above)by frozen or squash preparation; – Patients must be 18 to 70 years old, signed ICF; – At least 4 weeks after previous chemotherapy (6 weeks since nitrosoureas); – KPS ≥ 60; – Unilateral, Supratentorial, solitary lesion and not crossing the midline – No obvious important organ dysfunction: Hepatic function:Serum total bilirubin ≤1.5 times upper limit of laboratory normal; Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT)<2.5 times upper limit of laboratory normal; Renal function:Serum creatinine ≤1.5 times upper limit of laboratory normal; – Not Pregnant or lactating for women of childbearing potential. Exclusion Criteria:

  • Underwent cytoreductive surgery(excluded stereotactic biopsy); – With chemotherapy or brain radiotherapy history; – Tumor located at ventricular system, Open ventricle tumor cavity postoperatively; – Concomitant with other life-threatening diseases and with life expectancy <12 months; – Allergic to nitrosourea drugs; – With history of intracranial radiotherapy or implant chemotherapy; – With serious cardiac, pulmonary, hepatic and renal dysfunction, poor glycemic control; – Experienced > 3 times of Large epilepsy within one month preoperatively. – Investigators thought unsuitable for enrollment.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Shandong Lanjin Pharmaceuticals Co.,Ltd
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Yan H Sun, M.D., Principal Investigator, Beijing Tiantan Hospital
  • Overall Contact(s)
    • Yan H Sun, M.D., +86-1360-1389-945, sunyanhui1109@yahoo.com.cn

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.